Similarly, although HER2/neu gene amplification rates are higher in muscle-invasive disease compared with superficial disease, there is a wide variation in the literature of 4–32% (Coombs et al, 1991; Underwood et al, 1995; Mellon et al, 1996). The gene discussed is ERBB2; the disease is glycogen storage disease VI.